PRMT5 and leukemia: The inhibitors PJ-68 and HLCL-61 could specifically inhibit the activity of PRMT5 in leukaemia, through binding with the enzymatic active site in the SAM-domain24,25, which is the domain responsible for the interaction of PRMT5 with LINC01138.